The Impact of Inherited Retinal Diseases in the United States of America (US) and Canada from a Cost-of-Illness Perspective
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To estimate the annual cost of inherited retinal diseases (IRDs) in the United States of America (US) and Canada from a societal perspective - including costs to the health system, individual and family productivity costs, lost wellbeing and other societal economic costs - by setting and payer. Findings will inform the need for policy action to mitigate the impact of IRDs. METHODS: The costs of IRDs were estimated using a cost-of-illness methodology, based on the prevalence of IRDs in each country. Intangible costs of reduced wellbeing were also estimated using disability-adjusted life years which were then converted to monetary values using the value of a statistical life. RESULTS: Using base prevalence rates, total costs attributable to IRDs in the US were estimated to range between US$13,414.0 and US$31,797.4 million in 2019, comprising both economic costs (between US$4,982 and US$11,753.9 million; 37% of total costs) and wellbeing costs (between US$8,431.7 and US$20,043.6 million; 63%). Total costs attributable to IRDs in Canada were estimated to range between CAN$1637.8 and CAN$6687.5 million in 2019, comprising both economic costs (between CAN$566.6 and CAN$2,305.7 million; 34%) and wellbeing costs (between CAN$1,071.4 and CAN$4,381.9 million; 66% of total costs). CONCLUSION: The impact of IRDs in the US and Canada is substantial when considering both economic costs and reduced wellbeing. The wellbeing costs due to IRDs in the US and Canada are considerable, accounting for over 60% of total costs. Vision loss from IRDs often manifests in childhood, meaning some people live with vision impairment and blindness for their whole lives. Further research into current and emerging cost-effective therapies and interventions is required given the substantial economic burden faced by those living with vision loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“other international studies suggested that 81% to 90% of the costs associated with IRDs are indirect and intangible [80–84].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [81]
In the citing paper
“However, there is still a significant need for these products to reduce the high healthcare costs, economic burden, and costs to affected individuals and families and to improve patient well-being and quality of life.155”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
James, S. L., Abate, D., Abate, K. H., Abay, S. M., Abbafati, C., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdela, J., Abdelalim, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32279-7 · Cited by 13,867
Vos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Petty, R. E., Southwood, T. R. E., Manners, P. J., Baum, J., Glass, D. N., Goldenberg, J., He, X.-H., Maldonado-Cocco, J. A., Orozco-Alcalá, J., Prieur, A., et al. (2004) · PubMed · Cited by 4,176
The Elasticity of Taxable Income with Respect to Marginal Tax Rates: A Critical Review
Saez, E., Slemrod, J., & Giertz, S. H. (2012) · Journal of Economic Literature · doi:10.1257/jel.50.1.3 · Cited by 1,299
A 2020 vision of patient-centered primary care
Davis, K., Schoenbaum, S. C., & Audet, A.-M. (2005) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2005.0178.x · Cited by 683
Genes and mutations causing retinitis pigmentosa
Daiger, S. P., Sullivan, L. S., & Bowne, S. J. (2013) · Clinical Genetics · doi:10.1111/cge.12203 · Cited by 619
Centers for Medicare & Medicaid Services (CMS)
Services, U. S. C. F. M. M. (2013) · Cited by 318
Comparisons of Health Care Systems in the United States, Germany and Canada
Ridic, G., Gleason, S., & Ridic, O. (2012) · Materia Socio Medica · doi:10.5455/msm.2012.24.112-120 · Cited by 308
Zhang, X., Bullard, K. M., Cotch, M. F., Wilson, M. R., Rovner, B. W., McGwin, G., Owsley, C., Barker, L., Crews, J. E., & Saaddine, J. B. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.2597 · Cited by 293
Inherited Retinal Degenerations: Current Landscape and Knowledge Gaps
Duncan, J. L., Pierce, E. A., Laster, A. M., Daiger, S. P., Birch, D. G., Ash, J. D., Iannaccone, A., Flannery, J. G., Sahel, J. A., Zack, D. J., et al. (2018) · Translational Vision Science & Technology · doi:10.1167/tvst.7.4.6 · Cited by 257
Research works printed but not linked: 5
- Mayro, 2020, Eur J Ophthalmol, 1
- Fullerton, 2017, Natl Bureau Econ Res
- Baicker, 2011, Natl Bur Econ Res Bull Aging Health, 25, 39
- Canadian Arthritis Network. Canadian Arthritis Funding Landscape Review. Available from: https://www.arthrite.ca/AS/media/pdf/Researchers/Arthritis-Funding-Final-Final-Landscape-Review.pdf. Accessed March 10, 2021.
- Petty, 2004, J Rheumatol, 31, 390
Cited by
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Oxidative Stress: A Suitable Therapeutic Target for Optic Nerve Diseases?
Buonfiglio, F., Böhm, E. W., Pfeiffer, N., & Gericke, A. (2023) · Antioxidants · doi:10.3390/antiox12071465 · Cited by 78
Gene-Based Therapeutics for Inherited Retinal Diseases
Fenner, B. J., Tan, T., Barathi, V. A., Tun, S. B. B., Yeo, S. W., Tsai, A. S. H., Lee, S. Y., Cheung, C. M. G., Chan, C. M., Mehta, J. S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.794805 · Cited by 68
Stem cell therapy for inherited retinal diseases: a systematic review and meta-analysis
Chen, X., Xu, N., Li, J., Zhao, M., & Huang, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03526-x · Cited by 46
Gene Therapy for Inherited Retinal Diseases: From Laboratory Bench to Patient Bedside and Beyond
Brar, A. S., Parameswarappa, D. C., Takkar, B., Narayanan, R., Jalali, S., Mandal, S., Fujinami, K., & Padhy, S. K. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00862-2 · Cited by 48
Metadata
- Authors
- Gong, J., Cheung, S., Fasso-Opie, A., Galvin, O., Moniz, L. S., Earle, D., Durham, T., Menzo, J., Li, N., Duffy, S., Dolgin, J., Shearman, M. S., Fiorani, C., Banhazi, J., & Daly, A.
- Affiliations
- Foundation Fighting Blindness (US)
- Applied Genetic Technologies (United States) (US)
- Novartis (Switzerland) (CH)
- Corresponding author
- Daly, Avril
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2021-07
- Volume
- Volume 15
- Pages
- 2855-2866
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- PMC
- PMC8257071
- OpenAlex
- W3175694094
- Cited by
- 64
- References
- 19
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 17 · 2023: 14 · 2022: 6
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical ophthalmology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- inherited retinal disease, economic burden, disability-adjusted life years, value of a statistical life, vision loss, productivity costs, health system costs, blindness, prevalence, United States, Canada
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Impact of Inherited Retinal Diseases in the United States of America (US) and Canada from a Cost-of-Illness Perspective. https://app.cochat.ai/papers/10.2147/opth.s313719
- The paper
- Gong, J., Cheung, S., Fasso-Opie, A., Galvin, O., Moniz, L. S., Earle, D., Durham, T., Menzo, J., Li, N., Duffy, S., Dolgin, J., Shearman, M. S., Fiorani, C., Banhazi, J., & Daly, A. (2021). The Impact of Inherited Retinal Diseases in the United States of America (US) and Canada from a Cost-of-Illness Perspective. Clinical Ophthalmology. https://doi.org/10.2147/opth.s313719
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

